performance Statement of income Consolidated Financial Statements for Quarter 2 of 2020 Quarter 2 of 2019 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million
decreased from Q4–2021, representing a decrease of 221.1 MB or 13.6% and it also decreased from Q1–2021, representing a decrease of 425.0 MB or 23.3% mainly because during the Q1-2022, the delivered projects
rate in revenue which was 10. 8% , due to the decrease in gross profit margin of delivered projects in Q2–2024. While in Q2-2024 the changes rate in net profit compared to Q2-2024 was 12.8%. It was
date on which the claimant files the complaint, unless the claimant agrees to extend such period; or 3. the claimant is not satisfied with the compliant resolution. Clause 7. In filing the dispute to the
from the date on which the claimant files the complaint, unless the claimant agrees to extend such period; or 3. the claimant is not satisfied with the compliant resolution. Clause 7. In filing the
(Before Change) Reappraisal Basis (After Change) Increase (Decrease) Assets - Lands - Allowance for Impairment Losses of Lands 553.29 - 795.12 - 249.70 (7.87) Liabilities - Deferred tax liabilities - 49.94
Exchange of Thailand In accordance with the resolution of the Board of Directors Meeting of Inter Pharma Public Company Limited ("the Company") No. 4/2020, held on 8th June 2020, has approved the Company to
expansion of company’s internal activities. Nevertheless, the rate of increase is less than the growth rate of company’s revenue; therefore, SG&A/Sales decrease from 12.77% in Q3/2018 to 11.00% in Q3/2019. 3
focus more on doing projects with the public sector has caused the company’s back logs to decrease by 47.57 million baht between the year ending December 31st, 2017 and December 31st, 2018. The reduction